These results led us to conclude that, although ERK5 might contribute to controlling the expression level of certain epithelial and mesenchymal markers, the pathological context under which inhibition of the ERK5 pathway is sufficient to reprogram an epithelial phenotype from an aggressive mesenchymal breast cancer model remains unknown. Here, MAPK7 is linked to breast cancer.